Institution
Hospital General Universitario Gregorio Marañón
Healthcare•Madrid, Spain•
About: Hospital General Universitario Gregorio Marañón is a healthcare organization based out in Madrid, Spain. It is known for research contribution in the topics: Population & Transplantation. The organization has 11975 authors who have published 12386 publications receiving 244847 citations.
Topics: Population, Transplantation, Medicine, Myocardial infarction, Cancer
Papers published on a yearly basis
Papers
More filters
TL;DR: The limited clinical data suggest that the addition of HMOs to infant formula seems to be safe and well tolerated, inducing a normal growth and suggesting a trend towards health benefits.
Abstract: The authors reviewed the published evidence on the presence of oligosaccharides in human milk (HMO) and their benefits in in vitro and in vivo studies. The still limited data of trials evaluating the effect of mainly 2′-fucosyllactose (2′-FL) on the addition of some of HMOs to infant formula were also reviewed. PubMed was searched from January 1990 to April 2018. The amount of HMOs in mother’s milk is a dynamic process as it changes over time. Many factors, such as duration of lactation, environmental, and genetic factors, influence the amount of HMOs. HMOs may support immune function development and provide protection against infectious diseases directly through the interaction of the gut epithelial cells or indirectly through the modulation of the gut microbiota, including the stimulation of the bifidobacteria. The limited clinical data suggest that the addition of HMOs to infant formula seems to be safe and well tolerated, inducing a normal growth and suggesting a trend towards health benefits. HMOs are one of the major differences between cow’s milk and human milk, and available evidence indicates that these components do have a health promoting benefit. The addition of one or two of these components to infant formula is safe, and brings infant formula closer to human milk. More prospective, randomized trials in infants are need to evaluate the clinical benefit of supplementing infant formula with HMOs.
179 citations
Memorial Sloan Kettering Cancer Center1, University of Colorado Boulder2, Aix-Marseille University3, University of Michigan4, Texas Oncology5, Swansea University6, European Institute of Oncology7, Cross Cancer Institute8, Princess Margaret Cancer Centre9, Hospital General Universitario Gregorio Marañón10, Netherlands Cancer Institute11, Katholieke Universiteit Leuven12, University of Sydney13, University of Paris14, Peter MacCallum Cancer Centre15, University of California, San Diego16, Bristol-Myers Squibb17, The Royal Marsden NHS Foundation Trust18, Harvard University19
TL;DR: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolaumab alone versus IPILimumab as discussed by the authors.
Abstract: PURPOSEIn the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year effi...
179 citations
TL;DR: Despite having significant cardiac risk factors, only one-half of young AMI patients believed they were at risk for heart disease before their event, and even fewer discussed their risks or risk modification with their health care providers.
179 citations
TL;DR: New methods based on the speed of bacterial growth to detectable levels of micro-organisms in conventional blood cultures are a new and interesting way of assessing catheter-related infections.
178 citations
Authors
Showing all 12014 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| David H. Adams | 155 | 1613 | 117783 |
| Stefanie Dimmeler | 147 | 574 | 81658 |
| Stuart J. Pocock | 145 | 684 | 143547 |
| M. I. Martínez | 134 | 1251 | 79885 |
| Guy A. Rouleau | 129 | 884 | 65892 |
| Jose L. Jimenez | 124 | 654 | 64226 |
| Antoni Torres | 120 | 1238 | 65049 |
| Paul P. Tak | 112 | 591 | 57689 |
| Luis A. Diaz | 111 | 596 | 75036 |
| Frans Van de Werf | 109 | 747 | 63537 |
| José Luis Zamorano | 105 | 695 | 133396 |
| Francisco Sánchez-Madrid | 102 | 527 | 43418 |
| Francesco Locatelli | 99 | 820 | 42454 |
| Roberto M. Lang | 96 | 823 | 56638 |
| Carlos Simón | 95 | 589 | 31147 |